Engaging in regular exercise, practicing meditation or mindfulness, and seeking the help of a therapist are all effective ways to reduce stress
(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
Thats real health
2.5 mL vial at 5 mg/mL (12.5 mg total semaglutide): 5 mL vial at 5 mg/mL (25 mg total semaglutide): At maintenance doses (1.7 to 2.4 mg), you go through vials faster
Novo and competitor Eli Lilly have established the market in obesity and weight loss with GLP-1s Wegovy and Zepbound, respectively
Some patients also experience reduced appetite and early satiety, which can result in inadequate nutritional intake and subsequent weakness or dizziness